A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
Status
Conditions
Details and patient eligibility
About
The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.
Full description
The plan is to collect both blood and tumor samples from the patient's lung cancer in order to validate this technology in detecting circulating tumor cells. The investigators will also obtain a postoperative blood sample to see if there is a decrease in the overall circulating tumor cell measurement once the tumor has been surgically removed.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Stage IB and above non-small cell lung cancer or metastatic lung cancer
- Age >18 years old
- Willing and able to consent to study
- No prior history of neoadjuvant therapy.
Exclusion criteria
- Age <18 years old
- Unable to provide consent
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal